Home/Pipeline/iMAC Platform Programs

iMAC Platform Programs

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Shoreline Biosciences

About Shoreline Biosciences

Shoreline Biosciences is a private, pre-clinical stage biotech founded in 2020 and headquartered in San Diego, CA. The company is pioneering a platform for developing homogeneous, scalable, 'off-the-shelf' cellular immunotherapies using engineered iPSC-derived natural killer cells and macrophages. Its approach aims to overcome key limitations of autologous cell therapies, such as manufacturing complexity, high cost, and product variability. Shoreline is building a pipeline of candidates targeting cancer and other serious diseases, positioning itself in the competitive but high-potential allogeneic cell therapy space.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed